Astria Therapeutics (ATXS) EBITDA (2014 - 2025)
Astria Therapeutics (ATXS) EBITDA from Jun 30, 2014 to Sep 30, 2025. The TTM Astria Therapeutics (ATXS) EBITDA is -$124M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Astria Therapeutics (ATXS) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +23.98% |
| 3 Years TTM | +37.17% |
| 5 Years TTM | +28.49% |
| 10 Years TTM | +18.74% |
| All Time TTM | +19.46% |
Annual EBITDA change of Astria Therapeutics (ATXS)
| Year | EBITDA | Change |
|---|---|---|
| 2025 | -$98M | +4.39% |
| 2024 | -$94M | +29.32% |
| 2023 | -$73M | +40.63% |
| 2022 | -$52M | -73.41% |
| 2021 | -$195M | +422.55% |
| 2020 | -$37M | +37.84% |
| 2019 | -$27M | +3.09% |
| 2018 | -$26M | -2.02% |
| 2017 | -$27M | -23.81% |
| 2016 | -$35M | +11.76% |
| 2015 | -$31M | +46.80% |
| 2014 | -$21M | +20.39% |
| 2013 | -$18M | N/A |
Comparison Astria Therapeutics (ATXS) five years EBITDA CAGR with competitors
Astria Therapeutics (ATXS) five years EBITDA CAGR is 28.49%.